<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085017</url>
  </required_header>
  <id_info>
    <org_study_id>5160386</org_study_id>
    <secondary_id>16042</secondary_id>
    <nct_id>NCT03085017</nct_id>
  </id_info>
  <brief_title>Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery</brief_title>
  <official_title>Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized open-label study that will evaluate the effectiveness of the pliable
      and absorbable bone hemostats (BoneSeal®) on the reduction of bleeding from the sternal bone
      marrow in patients undergoing cardiothoracic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized open-label study that will evaluate the effectiveness of the pliable
      and absorbable bone hemostats (BoneSeal®) composed of synthetic materials and hydroxyapatite
      on the reduction of bleeding from the sternal bone marrow in patients undergoing Coronary
      Artery Bypass Grafting, with or without valve replacement or repair. This product will be
      compared to the similar, currently used product, Ostene®. Bleeding will be evaluated
      qualitatively by the surgeon as well as quantitatively by comparing pre- and post-operative
      hemoglobin levels, intra-operative and post-operative blood product usage, and post-operative
      chest tube output. A 30 day follow-up will be conducted to evaluate the patient's tolerance
      of the product, possible complications, or infection. Additionally, surgeons will be asked to
      comment on the ease of use of the product.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Anticipated">August 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemostatic Action</measure>
    <time_frame>3-6 hours</time_frame>
    <description>Qualitative determination of bleeding and hemostatic action during application graded by the surgeon using the mild, moderate, and severe for bleeding and complete, moderate, minimal, and failure for hemostatic action.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Re-bleed</measure>
    <time_frame>3-6 hours</time_frame>
    <description>Occurrence of re-bleeding during the operation will be noted. Reapplication of product will not occur.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative hemoglobin</measure>
    <time_frame>3-6 hours</time_frame>
    <description>Postoperative hemoglobin as compared to baseline preoperative readings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood product transfusion quantities</measure>
    <time_frame>3-6 hours</time_frame>
    <description>Intra-operative and post-operative blood product transfusion quantities in total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical Site Drainage</measure>
    <time_frame>24 hours</time_frame>
    <description>Post-operative chest tube output</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post Operative Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Sternal wound infection or other complications within 30 days post procedure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>Ostene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BoneSeal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BoneSeal</intervention_name>
    <description>BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.</description>
    <arm_group_label>BoneSeal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ostene</intervention_name>
    <description>OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.</description>
    <arm_group_label>Ostene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consent given by patient prior to surgery

          2. Adult patients over 45 years

          3. Subjects requiring elective, prescheduled or urgent open heart surgery requiring a
             sternotomy including, but not limited to CABG, valve repair, valve replacement

        Exclusion Criteria:

          1. An immune system disorder

          2. Known hypersensitivity to components in BoneSeal® or Ostene®

          3. Patients undergoing emergency surgery

          4. Patients undergoing aortic dissection

          5. No consent given
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nahidh W Hasaniya, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nahidh W Hasaniya, MD, PhD</last_name>
    <phone>909-558-4355</phone>
    <email>nhasaniya@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa L Ayer Miller, MS</last_name>
    <phone>9095584355</phone>
    <email>vayermiller@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nahidh Hasaniya, MD,PhD</last_name>
      <phone>909-558-4354</phone>
      <email>nhasaniya@llu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa L Ayer Miller, MS</last_name>
      <phone>9095584355</phone>
      <email>vayermiller@llu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Light R. Hemostasis in neurosurgery. Journal of neurosurgery. 1945; 2(5): p. 414-34.</citation>
  </reference>
  <reference>
    <citation>Nelson DR, Buxton TB, Luu QN, Rissing JP. The promotional effect of bone wax on experimental Staphylococcus aureus osteomyelitis. J Thorac Cardiovasc Surg. 1990 Jun;99(6):977-80.</citation>
    <PMID>2359338</PMID>
  </reference>
  <reference>
    <citation>Sudmann B, Bang G, Sudmann E. Histologically verified bone wax (beeswax) granuloma after median sternotomy in 17 of 18 autopsy cases. Pathology. 2006 Apr;38(2):138-41.</citation>
    <PMID>16581654</PMID>
  </reference>
  <reference>
    <citation>Johnson P, Fromm D. Effects of bone wax on bacterial clearance. Surgery. 1981 Feb;89(2):206-9.</citation>
    <PMID>7006134</PMID>
  </reference>
  <reference>
    <citation>Orgill DP, Ehret FW, Regan JF, Glowacki J, Mulliken JB. Polyethylene glycol/microfibrillar collagen composite as a new resorbable hemostatic bone wax. J Biomed Mater Res. 1998 Mar 5;39(3):358-63.</citation>
    <PMID>9468043</PMID>
  </reference>
  <reference>
    <citation>Solheim E, Pinholt EM, Andersen R, Bang G, Sudmann E. The effect of a composite of polyorthoester and demineralized bone on the healing of large segmental defects of the radius in rats. J Bone Joint Surg Am. 1992 Dec;74(10):1456-63.</citation>
    <PMID>1469005</PMID>
  </reference>
  <reference>
    <citation>Solheim E, Pinholt EM, Bang G, Sudmann E. Effect of local hemostatics on bone induction in rats: a comparative study of bone wax, fibrin-collagen paste, and bioerodible polyorthoester with and without gentamicin. J Biomed Mater Res. 1992 Jun;26(6):791-800.</citation>
    <PMID>1527101</PMID>
  </reference>
  <reference>
    <citation>Sugamori T, Iwase H, Maeda M, Inoue Y, Kurosawa H. Local hemostatic effects of microcrystalline partially deacetylated chitin hydrochloride. J Biomed Mater Res. 2000 Feb;49(2):225-32.</citation>
    <PMID>10571909</PMID>
  </reference>
  <reference>
    <citation>Wilkinson HA, Baker S, Rosenfeld S. Gelfoam paste in experimental laminectomy and cranial trephination: hemostasis and bone healing. J Neurosurg. 1981 May;54(5):664-7.</citation>
    <PMID>7229706</PMID>
  </reference>
  <reference>
    <citation>Magyar CE, Aghaloo TL, Atti E, Tetradis S. Ostene, a new alkylene oxide copolymer bone hemostatic material, does not inhibit bone healing. Neurosurgery. 2008 Oct;63(4 Suppl 2):373-8; discussion 378. doi: 10.1227/01.NEU.0000316859.03788.44.</citation>
    <PMID>18981846</PMID>
  </reference>
  <reference>
    <citation>Vestergaard RF, Brüel A, Thomsen JS, Hauge EM, Søballe K, Hasenkam JM. The influence of hemostatic agents on bone healing after sternotomy in a porcine model. Ann Thorac Surg. 2015 Mar;99(3):1005-11. doi: 10.1016/j.athoracsur.2014.10.016. Epub 2015 Jan 16.</citation>
    <PMID>25601654</PMID>
  </reference>
  <reference>
    <citation>Higashi S, Yamamuro T, Nakamura T, Ikada Y, Hyon SH, Jamshidi K. Polymer-hydroxyapatite composites for biodegradable bone fillers. Biomaterials. 1986 May;7(3):183-7.</citation>
    <PMID>3013326</PMID>
  </reference>
  <reference>
    <citation>Overgaard S, Søballe K, Lind M, Bünger C. Resorption of hydroxyapatite and fluorapatite coatings in man. An experimental study in trabecular bone. J Bone Joint Surg Br. 1997 Jul;79(4):654-9.</citation>
    <PMID>9250760</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Nahidh Hasaniya</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 8, 2018</submitted>
    <returned>April 3, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

